\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[greek,ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Biofield Energy Therapy: Role in Multiple Organ Health~ Specific
Biomarkers in Cell-Based Assay}



\author[1]{Sakina Aleemah Ansari}%
\author[2]{Mahendra Kumar Trivedi}%
\author[1]{Alice Branton}%
\author[1]{Dahryn Trivedi}%
\author[1]{Gopal Nayak}%
\author[1]{Mayank Gangwar}%
\author[1]{Snehasis Jana}%
\affil[1]{Affiliation not available}%
\affil[2]{Trivedi Global, Inc}%


\vspace{-1em}



  
  \date{May 18, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
The major cause of high rate of mortality is the multiple organ
dysfunction among critical care healthcare services. The aim of the
current study was to evaluate the impact of the Biofield Energy Treated
test formulation using standard and specific cell lines related with
vital organs functioning. The test formulation and the specific cell
media was divided into two parts; one part was untreated (UT) and other
part received the Biofield Energy Treatment remotely by a renowned
Biofield Energy Healer, Sakina Aleemah Ansari, USA and labeled as the
Biofield Energy Treated (BT) test formulation/media. The test
formulation was tested against various activities using cell line assay
in their specific medium (Med). The test formulation was tested for cell
viability, and the results showed that the test formulation at tested
concentrations was found safe and non-toxic. Cytoprotective activity
showed improved cellular restoration by 105.4\% (at 25 \selectlanguage{greek}µ\selectlanguage{english}g/mL), 32.8\%
(at 25 \selectlanguage{greek}µ\selectlanguage{english}g/mL), and 151.8\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the UT-Med + BT-TI, BT-Med +
UT-TI, and BTMed + BT-TI groups respectively, as compared to the
untreated test group in the human cardiac fibroblasts cells (HCF) cells,
while improved restoration of cell viability by 22.4\% (at 25.5 \selectlanguage{greek}µ\selectlanguage{english}g/mL),
67.1\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL), and 72.9\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the UT-Med + BT-TI,
BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to
the untreated test group in HepG2 cells. Cellular restoration in A549
cells was improved by 9.3\%, 70.4\%, and 14.1\% at 0.1, 1, and 25.5
\selectlanguage{greek}µ\selectlanguage{english}g/mL respectively, in the BT-Med + UT-TI group, while 3\% and 4.6\%
improved cellular restoration was reported at 10 and 25.5 \selectlanguage{greek}µ\selectlanguage{english}g/mL
respectively, at BT-Med + BT-TI groups as compared to the untreated test
group. ALP activity in Ishikawa cells was significantly increased by
68.4\%, 41.1\%, and 18.8\% at 0.1, 10, and 50 \selectlanguage{greek}µ\selectlanguage{english}g/mL respectively, in the
UT-Med + BTTI group, while in MG-63 cells showed maximum increased ALP
activity by 92.7\%, 84.5\%, and 93.2\% respectively in the UT-Med +
BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI group respectively, at 50
\selectlanguage{greek}µ\selectlanguage{english}g/mL as compared to the untreated group. The maximum percent cellular
protection of HCF (heart) cells (decreased of LDH activity) was
significantly increased by 51.6\%, 88.7\%, and 53.7\% in the UT-Med +
BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 10
\selectlanguage{greek}µ\selectlanguage{english}g/mL as compared to the untreated group. Alanine amino transferase
(ALT) activity was reported in terms of percent cellular protection of
HepG2 (liver) cells. The test data showed improved HepG2 cells
protection (represents decreased ALT activity) by 33\%, 90.2\%, and
72.1\% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups
respectively, at 25 \selectlanguage{greek}µ\selectlanguage{english}g/mL as compared to the untreated test group.
Percentage cellular protection of A549 (lungs) cells (represents
increased of SOD activity) was increased by 21.5\% at 25.5 \selectlanguage{greek}µ\selectlanguage{english}g/mL in the
UT-Med + BT-TI, while 33.4\%, 25.8\%, and 21.5\% at 1, 10, and 25.5
\selectlanguage{greek}µ\selectlanguage{english}g/mL respectively, in the BT-Med + UT-TI group, and 12.8\% increased
SOD activity at 25.5 \selectlanguage{greek}µ\selectlanguage{english}g/mL in the BT-Med + BT-TI groups as compared to
the untreated group. Serotonin level was significantly increased 137.4\%
(at 0.1 \selectlanguage{greek}µ\selectlanguage{english}g/mL), 65.4\% (at 0.1 \selectlanguage{greek}µ\selectlanguage{english}g/mL), and 77.3\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the
UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups, respectively
compared to untreated test group in human neuroblastoma cells (SH-SY5Y).
However, the relative quantification (RQ) of vitamin D receptor (VDR)
was significantly increased by 24.2\% (at 1 \selectlanguage{greek}µ\selectlanguage{english}g/mL), 213.7\% (at 10
\selectlanguage{greek}µ\selectlanguage{english}g/mL), and 328.7\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the UT-Med + BT-TI, BT-Med + UT-TI,
and BT-Med + BT-TI groups, respectively as compared to the untreated in
MG-63 cells. Thus, the data concluded that The Trivedi Effect\selectlanguage{ngerman}® would be
significantly useful for improving multiple organs health, which can be
used for many coronary artery diseases, arrhythmias, congenital heart
disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis,
asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc%
\end{abstract}\selectlanguage{ngerman}%



\sloppy


\textbf{Journal Name:}~Annals of Advanced Biomedical Sciences

\textbf{Date of Publication:}~23-07-2019

\textbf{ISSN:}~2641-9459

\textbf{Volume:}~2

\textbf{Issue:}~5

\textbf{\textbf{Journal Web
URL:}}~\url{https://medwinpublishers.com/AABSc/volume.php?volumeId=191\&issueId=658}

\textbf{~\textbf{Journal PDF
URL:}}~\url{https://medwinpublishers.com/AABSc/AABSc16000136.pdf}

\textbf{Publisher:}~Medwin

\textbf{Keywords:}~The Trivedi Effect\selectlanguage{ngerman}®; Biofield Energy Treatment; Organ
health; Multiple organ failure; Bone health

\textbf{Citation:}~Sakina Aleemah Ansari, et al. Biofield Energy
Therapy: Role in Multiple Organ Health Specific Biomarkers in Cell-Based
Assay. Ann Adv Biomed Sci 2019, 2(5): 000136.

\selectlanguage{english}
\FloatBarrier
\end{document}

